The CMRI study demonstrated that FICZ treatment prevents the increase in LVM in the TAC group, which is consistent with the results for the postmortem HW and HW/TL ratio and fits well with the results for Nppa expression. This evidence concerns the gene NPPA and persistent truncus arteriosus.